Comparative Pharmacology
Head-to-head clinical analysis: BENZPHETAMINE HYDROCHLORIDE versus MYDAYIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZPHETAMINE HYDROCHLORIDE versus MYDAYIS.
BENZPHETAMINE HYDROCHLORIDE vs MYDAYIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzphetamine is a sympathomimetic amine that acts as a central nervous system stimulant. It primarily works by promoting the release of norepinephrine and dopamine from presynaptic nerve terminals in the brain, which leads to appetite suppression and increased energy expenditure.
MYDAYIS is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mechanism of action in ADHD is not fully elucidated, but they block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase their release into the extraneuronal space.
25-50 mg orally once daily, may increase by 25 mg increments at weekly intervals; maximum 100 mg/day.
Oral, 12.5 mg or 25 mg once daily in the morning.
None Documented
None Documented
Benzphetamine has a long elimination half-life of 10-16 hours (up to 20 hours in some individuals). Its active metabolites (amphetamine and methamphetamine) have half-lives of 10-12 hours and 9-11 hours, respectively. Steady state is reached within 3-4 days. The long half-life supports once-daily dosing but carries risk of accumulation with renal impairment.
12 hours for d-methylphenidate; 3-4 hours for l-methylphenidate; clinical context: d-isomer provides extended coverage; l-isomer contributes minimal activity
Primarily renal (approximately 70-90% of the dose excreted unchanged in urine, with the remainder as metabolites including amphetamine and methamphetamine). Fecal excretion is minimal (<5%).
Renal (approx. 90% as unchanged drug and 10% as inactive metabolites); fecal <5%
Category C
Category C
CNS Stimulant
CNS Stimulant